Wy-14643

• CAT Number: I003812
• CAS Number: 50892-23-4
• Molecular Formula: C14H14ClN3O2S
• Molecular Weight: 323.8
• Purity: ≥95%
• Target: PPAR
• Solubility: DMSO: ≤ 15 mg/mL
• Storage: Room Temperature
• IC50: 36.5 μM (for PPARα), 53.7 μM (for PPARγ) [2]
• IUPAC Name: 2-[4-chloro-6-(2,3-dimethylanilino)pyrimidin-2-yl]sulfanylacetic acid
• InChI: InChI=1S/C14H14ClN3O2S/c1-8-4-3-5-10(9(8)2)16-12-6-11(15)17-14(18-12)21-7-13(19)20/h3-6H,7H2,1-2H3,(H,19,20)(H,16,17,18)
• InChIKey: SZRPDCCEHVWOJX-UHFFFAOYSA-N
• SMILES: CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C

WY 14643 (Cat No.:I003812) is a potent activator of peroxisome proliferator-activated receptor alpha (PPARα). It has an EC50 value of 1.5 μM, indicating its strong affinity for PPARα. Activation of PPARα by WY 14643 leads to various biological effects, including the regulation of lipid metabolism and inflammation. This compound has been extensively studied for its potential therapeutic applications in treating metabolic disorders such as dyslipidemia and insulin resistance.

Reference

1:WY-14643, a selective agonist of peroxisome proliferator-activated receptor-α, ameliorates lipopolysaccharide-induced depressive-like behaviors by preventing neuroinflammation and oxido-nitrosative stress in mice. Yang R, Wang P, Chen Z, Hu W, Gong Y, Zhang W, Huang C.Pharmacol Biochem Behav. 2017 Feb;153:97-104. doi: 10.1016/j.pbb.2016.12.010. Epub 2016 Dec 23. PMID: 28017641 2:PPAR-α Agonist WY-14643 Inhibits LPS-Induced Inflammation in Synovial Fibroblasts via NF-kB Pathway. Huang D, Zhao Q, Liu H, Guo Y, Xu H.J Mol Neurosci. 2016 Aug;59(4):544-53. doi: 10.1007/s12031-016-0775-y. Epub 2016 Jun 24. PMID: 27339772 3:PPARα Agonist WY-14643 Induces SIRT1 Activity in Rat Fatty Liver Ischemia-Reperfusion Injury. Pantazi E, Folch-Puy E, Bejaoui M, Panisello A, Varela AT, Rolo AP, Palmeira CM, Roselló-Catafau J.Biomed Res Int. 2015;2015:894679. doi: 10.1155/2015/894679. Epub 2015 Oct 11. PMID: 26539534 Free PMC Article4:Possible role of intestinal fatty acid oxidation in the eating-inhibitory effect of the PPAR-α agonist Wy-14643 in high-fat diet fed rats. Karimian Azari E, Leitner C, Jaggi T, Langhans W, Mansouri A.PLoS One. 2013 Sep 17;8(9):e74869. doi: 10.1371/journal.pone.0074869. eCollection 2013. PMID: 24069361 Free PMC Article5:Delayed cardioprotective effects of WY-14643 are associated with inhibition of MMP-2 and modulation of Bcl-2 family proteins through PPAR-α activation in rat hearts subjected to global ischaemia-reperfusion. Barlaka E, Ledvényiová V, Galatou E, Ferko M, Čarnická S, Ravingerová T, Lazou A.Can J Physiol Pharmacol. 2013 Aug;91(8):608-16. doi: 10.1139/cjpp-2012-0412. Epub 2013 Mar 3. PMID: 23889688 6:Activation of PPARα by Wy-14643 ameliorates systemic lipopolysaccharide-induced acute lung injury. Yoo SH, Abdelmegeed MA, Song BJ.Biochem Biophys Res Commun. 2013 Jul 5;436(3):366-71. doi: 10.1016/j.bbrc.2013.05.073. Epub 2013 May 29. PMID: 23727576 Free PMC Article7:Tissue expression of PPAR-α isoforms in Scophthalmus maximus and transcriptional response of target genes in the heart after exposure to WY-14643. Urbatzka R, Galante-Oliveira S, Rocha E, Castro LF, Cunha I.Fish Physiol Biochem. 2013 Aug;39(4):1043-55. doi: 10.1007/s10695-012-9761-7. Epub 2012 Dec 25. PMID: 23266856 8:WY-14643, a Potent Peroxisome Proliferator Activator Receptor-α PPAR-α Agonist Ameliorates the Inflammatory Process Associated to Experimental Periodontitis. Briguglio E, Di Paola R, Paterniti I, Mazzon E, Oteri G, Cordasco G, Cuzzocrea S.PPAR Res. 2010;2010:193019. doi: 10.1155/2010/193019. Epub 2010 Dec 27. PMID: 21253492 Free PMC Article9:Effects of WY-14643 on peroxisomal enzyme activity and hormone secretion in immortalized human trophoblast cells. Hashimoto F, Morita M, Iwasaki K, Takeda S, Hayashi H.Biol Pharm Bull. 2009 Jul;32(7):1278-82. PMID: 19571398 Free Article10:Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation. Senekeo-Effenberger K, Chen S, Brace-Sinnokrak E, Bonzo JA, Yueh MF, Argikar U, Kaeding J, Trottier J, Remmel RP, Ritter JK, Barbier O, Tukey RH.Drug Metab Dispos. 2007 Mar;35(3):419-27. Epub 2006 Dec 6. PMID: 17151188 Free Article